Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2026

Biliary intervention in oncology inpatients: timeliness and outcomes. (146558)

Nina Marquard-Karp 1 , Thomas Johnson 1 , Louisa Robinson 1 , Bridget Nielsen 1 , Liam Thorne 1 , Morteza Aghmesheh 1 2 , Melvin Chin 1 2
  1. Medical Oncology Department, Prince of Wales Hospital (POWH), Randwick, NSW, Australia
  2. Faculty of Medicine and Health, UNSW, Randwick, New South Wales, Australia

Biliary obstruction occurs in up to 90% and 56% of patients with pancreatic and gallbladder cancers respectively1. Biliary intervention (BI), stent or drain placement, is a possible treatment, particularly as a bridge to definitive treatment. 

Aim: To assess outcomes of BI in inpatients with malignant biliary obstruction and impact of delay in procedure.

Method: Retrospective audit of electronic medical records of Prince of Wales Hospital inpatients who underwent BI for malignant biliary obstruction between 01/01/25 and 12/04/26. Diagnosis of primary malignancy, treatment intent, number of business days between request and procedure, team performing procedure: Gastroenterology/Interventional Radiology, serum bilirubin and time-to-death following procedure were collected. Student’s T-test applied for comparison between groups.

Results: Eleven patients (6 cholangiocarcinoma, 3 pancreatic, 1 gastric and 1 colorectal cancer) underwent 35 procedures. Within 3 months of first BI procedure, 10/11 (91%) died. Three patients had treatment with curative intent (including the patient surviving >3 months). Seven patients received palliative chemotherapy and 1 neoadjuvant chemotherapy. Twelve procedures across 6 patients had a wait of >2 days, with no difference in average wait time (2.2 vs 2.8 business days) between Gastroenterology and Interventional Radiology. BI was associated with bilirubin decrease (average foldchange 0.616 +/- 0.298). No significant difference in mortality nor bilirubin foldchange post intervention was demonstrated in procedures done >2 days vs <2 days of waiting (p=0.383 and p=0.175, respectively). Bilirubin foldchange was not associated with mortality benefit.

Conclusion: While BI resulted in adequate serum bilirubin decrease, it conferred limited survival benefit, with 91% of patients dying within 3 months of intervention. Intervention team, delays in procedure and intent of treatment (curative/palliative) did not influence outcomes in this cohort. Study was limited by a small sample size from one centre. Further study on the selection of patients for BI is warranted.

  1. Varghese G, Kar M, Jamwal A, Sahu C. Outcomes and Risk Factors for Bacteriobilia in Cancer Patients Undergoing Endoscopic Retrograde Cholangiopancreatography of Malignant Biliary Obstruction at a Teaching Hospital in Northern India. Euroasian J Hepatogastroenterol. 2025;15(2):164-169. doi:10.5005/jp-journals-10018-1497